research use only

Kisspeptin-10 (human) GPR chemical

Name: Kisspeptin-10 (human)
Brand: Selleck Chemicals
SKU: E2037
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E2037

Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis, acts as a tumor metastasis suppressor via its receptor GPR54, inducing osteoblast differentiation via NFATc4-mediated BMP2 expression.

Chemical Structure

Molecular Weight: 1302.44

Jump to

Quality Control

Batch: E203701 DMSO]100 mg/mL]false]Water]25 mg/mL]false]Ethanol]Insoluble]false Purity: 99.53%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.53

Related Targets	CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas
Other GPR Inhibitors	ONC212 Fasiglifam(TAK-875) Hemihydrate GW9508 3-chloro-5-hydroxybenzoic Acid AH7614 TC-G-1008 (GPR39-C3) JMS-17-2 NE 52-QQ57 SNAP94847 hydrochloride AZD1981

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (76.77 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 25 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1302.44	Formula	C₆₃H₈₃N₁₇O₁₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	374675-21-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	GPR54
References	[1] https://pubmed.ncbi.nlm.nih.gov/29391507/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-06)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07321028	ENROLLING_BY_INVITATION	Cellular Injury and Post-Cryogenic Recovery; Cryogenic Cellular Stress; Cold-Induced Cellular Injury; Thermal Injury Response; Post-Thaw Viability Impairment; Osmotic Stress Injury; Biomechanical Injury Modeling (In-Vitro); Blunt Force Injuries to the Extremities (Cellular Injury Model); Tissue Damage and Recovery Pathways; Hypothermic Tissue Stress; Cellular Regeneration and Repair	Truway Health, Inc.	2025-12-10	EARLY_PHASE1
NCT00117936	NOT_YET_RECRUITING	Coronary Disease; Coronary Heart Disease; Myocardial Ischemia; Coronary Arteriosclerosis	Venturis Therapeutics, Inc.	2027-09-01	PHASE2
NCT07593859	RECRUITING	Healthy Adult Participants	Northeastern University	2026-02-01
NCT07659028	NOT_YET_RECRUITING	Prediabetes; Obesity & Overweight; Inflamation; Oxidative Stress	National and Kapodistrian University of Athens	2026-07-01
NCT07658352	NOT_YET_RECRUITING	B-Cell Non-Hodgkin Lymphoma	Shanghai Helioson Pharmaceutical Co., Ltd.	2026-06-26	PHASE1; PHASE2
NCT06914128	RECRUITING	MTAP-deleted Solid Tumors	Bayer	2025-03-21	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):